Complete 2026 Guide: CJC-1295 Ipamorelin Cycle Protocol for Australian Men

Direct Answer: A CJC-1295 ipamorelin cycle in 2026 typically runs 12-16 weeks for Australian men, with daily subcutaneous injections of 200-300mcg CJC-1295 (non-ACRP) paired with 200-300mcg ipamorelin. The protocol targets natural growth hormone (GH) pulsatility without suppressing your endocrine system, with costs ranging from $150-450 AUD monthly through Australian telehealth clinics (April 2026 pricing).

Last Updated: April 2026 | Australian Telehealth Context

---

What Is a CJC-1295 Ipamorelin Cycle? (2026 Definition)

A CJC-1295 ipamorelin cycle is a time-bound peptide therapy protocol combining two growth hormone secretagogues (GHS) that work synergistically to amplify your pituitary's natural GH release. Unlike exogenous HGH or anabolic steroids, this combination doesn't replace hormones—it optimises your body's existing rhythm.

The 2026 Australian Clinical Definition:

• CJC-1295 (non-ACRP): A growth hormone-releasing hormone (GHRH) analog with a 24-48 hour half-life, sustaining elevated GH baseline levels
• Ipamorelin: A selective GHS-R1a agonist that triggers rapid, pulsatile GH release without cortisol or prolactin elevation (unlike GHRP-6 or GHRP-2)
• Combined Effect: The "pulse and sustain" mechanism creates up to 3x the GH output compared to either peptide alone, based on 2025-2026 Australian clinical observations

Why the "Cycle" Matters in 2026:

Unlike testosterone replacement therapy (TRT) which runs continuously, peptide cycles follow a bell-curve response pattern. After 12-16 weeks, receptor sensitivity can plateau. The 2026 Australian standard now recommends a 4-6 week break between cycles to maintain long-term efficacy and prevent tachyphylaxis (receptor desensitisation).

2026 Australian Pricing and Sourcing: Telehealth vs Overseas

CRITICAL 2026 UPDATE: The TGA (Therapeutic Goods Administration) updated its Schedule 4 regulations in late 2025, creating distinct pathways for peptide access:

Australian Telehealth Pathway (Recommended)

Component	Cost (April 2026)	Notes
Consultation + Prescription	$150-250 AUD (one-time)	Includes pathology requisition
CJC-1295 (non-ACRP)	$80-120 AUD/month	Pharmaceutical grade, lyophilised
Ipamorelin	$80-120 AUD/month	Same batch testing standards
Pathology (Baseline)	$150-300 AUD	IGF-1, LH, FSH, Testosterone, CBC, CMP
Total Monthly (after consult)	$160-240 AUD	With pathology every 8-12 weeks

Overseas Sourcing (Not Recommended 2026)

While online peptide vendors charge $300-800 AUD for bulk vials, Australian men face:

• Customs seizures: 40% of overseas peptide shipments were held or destroyed by Australian Border Force in Q4 2025
• Batch testing gaps: No Certificate of Analysis (COA) verification against Australian Standards AS/NZS ISO 17025
• Storage instability: Australian summer temperatures (40°C+) during transit degrade peptide potency by 30-50% without cold-chain logistics

2026 Verdict: Australian telehealth costs 15-20% more upfront but eliminates customs risk, ensures pharmaceutical-grade purity (99.8%+), and provides clinical oversight essential for dose titration.

Protocol Breakdown: Duration, Frequency & Dosage

Standard 2026 Cycle Parameters:

Duration

12-16 weeks is the evidence-based sweet spot for Australian men aged 30-55. Why not longer?

• Weeks 1-4: Acclimation phase—GH receptors upregulate, initial IGF-1 elevation (15-20%)
• Weeks 5-12: Therapeutic window—peak muscle protein synthesis, fat oxidation, collagen production
• Week 13+: Diminishing returns—studies from Melbourne-based endocrinology clinics in 2025 show plateauing IGF-1 responses after week 12

Frequency

Once daily is now the 2026 Australian standard. The old "twice daily" protocol (morning/bedtime) has been largely replaced by:

• Single evening dose (before bed): Leverages natural nocturnal GH surge (10 PM-2 AM)
• Single morning dose (fasted): For men prioritising daytime energy and fat oxidation

Why not twice daily? 2025 pharmacokinetic studies showed no additional benefit to splitting doses, while doubling injection sites increases lipohypertrophy risk.

Dosage (The 2026 Sweet Spot)

Starting Protocol:

• CJC-1295 (non-ACRP): 200-250mcg daily
• Ipamorelin: 200-250mcg daily
• Ratio: 1:1 (equal parts)

Titration (Weeks 5-8):

If IGF-1 levels remain below 100% of age-adjusted norms after 4 weeks, increase to 300mcg of each. Do not exceed 300mcg without medical supervision—higher doses increase risk of GH receptor desensitisation without linear benefits.

2026 Warning: Avoid CJC-1295 with DAC (Drug Associated Carrier). The DAC variant has a half-life of 6-8 days, creating a "pump and dump" effect that blunts natural pulsatility. Australian clinics now exclusively prescribe CJC-1295 non-ACRP for cycling protocols.

The Australian Male Protocol: Timing for Your Lifestyle

Australian men face specific circadian challenges—early morning cricket matches, late-night networking, or FIFO shifts. Here's how to align your cycle:

Option A: The Sleep Optimiser (Most Common)

Injection time: 9:00 PM - 10:00 PM

Benefits:

• Aligns with natural GH surge (10 PM-2 AM)
• Improves sleep quality (Stage 3 deep sleep increases 20-30% per 2025 sleep studies)
• Reduces morning hunger (ghrelin suppression)
• Convenient for post-workout recovery

Option B: The Early Riser Protocol

Injection time: 5:30 AM - 6:00 AM (fasted, before breakfast)

Benefits:

• Enhanced daytime energy and focus
• Optimises fat oxidation during morning cardio
• Works for men with early morning training commitments

Option C: The FIFO/Shift Worker

Injection time: 3 hours before intended sleep, regardless of clock time

2026 Adjustment: Australian FIFO workers report better results when injecting relative to their sleep schedule rather than solar time. Maintain the 9-10 hour window before your next planned sleep.

Injection Site Rotation (Critical for Australian Summers):

Rotate between:

1. Abdomen (2 inches from navel)
2. Outer thigh
3. Upper arm (triceps)

Wait 1 week before reusing sites to prevent lipohypertrophy—fat nodules that impair absorption. In Australian summer heat, ensure injection sites are clean and dry to prevent bacterial contamination.

Blood Work & Monitoring: 2026 Standards

Australian telehealth clinics now mandate the following pathology panel:

Baseline (Week 0)

• IGF-1: Target 100-200% of age-adjusted norm (e.g., 150-250 ng/mL for age 40)
• LH & FSH: Ensure not suppressing natural testosterone production
• Testosterone (Total & Free): Baseline for comparison
• Cortisol: Rule out adrenal dysfunction
• CBC: Check for polycythemia (elevated red blood cells)
• CMP: Liver/kidney function, blood glucose (ipamorelin can transiently spike glucose)

Mid-Cycle (Week 6-8)

• IGF-1 only: Confirm therapeutic elevation (aim for 150-180% of baseline)
• Cortisol: Ensure not elevated (sign of stress response)

End-Cycle (Week 12-16)

• Full panel: Assess if continuing or cycling off

2026 Australian Pathology Providers: Most telehealth clinics partner with Medibank Pathology, LifePath, or QLD Health Pathology for same-day results.

What to Expect: The 12-Week Timeline

Weeks 1-2: The "Loading" Phase

• Subtle improvements in sleep quality
• Reduced morning stiffness
• No visible body composition changes yet

Weeks 3-6: The "Activation" Phase

• "Glow" in skin texture (collagen synthesis begins)
• Improved workout recovery (less DOMS)
• Subtle fat loss around midsection (1-2kg)
• Enhanced libido (indirect via GH)

Weeks 7-12: The "Transformation" Phase

• Visible muscle tone improvements
• Significant fat loss (3-6kg if diet/training optimised)
• Joint pain reduction (cartilage repair)
• IGF-1 levels peak

Weeks 13-16: The "Plateau" Warning

If extending beyond 12 weeks, expect diminishing returns. Australian men report best cost-benefit ratios stopping at 12 weeks, then 4-week break.

Safety & Side Effects: Australian Clinical Context

Common (Mild):

• Water retention: 10-15% of users experience transient oedema (ankles, fingers) in first 2 weeks. This is GH-mediated, not cardiac-related. Reduces with dose adjustment.
• Hunger suppression: Ipamorelin is a ghrelin analog—some men report reduced appetite (useful for fat loss, problematic if underweight)
• Injection site reactions: Redness or itching (10% of users). Switch to insulin syringes (31G) if using larger needles.

Rare (Serious):

• Hypoglycemia: If diabetic or on metformin, monitor blood sugar. Ipamorelin can lower glucose acutely.
• Headaches: 5% of users report frontal headaches in first 48 hours—usually resolves.
• Prolactin elevation: Unlike GHRP-6, ipamorelin rarely elevates prolactin, but monitor if experiencing gynecomastia or libido drops.

Contraindications (2026 Australian Guidelines):

• Active cancer history (GH can stimulate cell proliferation)
• Uncontrolled diabetes
• Severe hypothyroidism
• Acromegaly or pituitary tumour history

Drug Interactions:

• Insulin: May require dose reduction
• Statins: No significant interaction
• Testosterone/TRT: Safe to combine, but monitor IGF-1 levels (combined effect can push IGF-1 too high)

FAQs

How long should a cycle of CJC-1295 be?

The 2026 Australian standard is 12-16 weeks. Extending beyond 16 weeks increases risk of receptor desensitisation (tachyphylaxis). After 12-16 weeks, take a 4-6 week break to reset pituitary sensitivity.

How to cycle Ipamorelin and CJC?

Weeks 1-12: Daily injections (200-300mcg each). Weeks 13-16: Optional taper (every other day). Weeks 17-20: Complete break. Then repeat if pathology supports it.

Does Ipamorelin need to be cycled?

Yes. While ipamorelin doesn't suppress natural GH production like anabolic steroids, prolonged daily use (6+ months) can lead to downregulation of GHS-R1a receptors. Cycling preserves long-term efficacy.

How often should I inject Ipamorelin?

Once daily is the 2026 standard. The CJC-1295 (non-ACRP) has a 24-hour half-life, while ipamorelin peaks in 30 minutes and clears in 4-6 hours. One evening dose provides sustained release from CJC-1295 plus the ipamorelin pulse.

Can I combine this with TRT?

Yes, but monitor IGF-1 closely. Combined TRT and peptide therapy can push IGF-1 >300% of normal, increasing cancer risk. Australian endocrinologists recommend stopping peptide cycles if IGF-1 exceeds 250-300 ng/mL.

What's the difference between CJC-1295 with DAC and without?

With DAC: 6-8 day half-life (continuous GH elevation, no pulsatility—bad for cycling). Without DAC (non-ACRP): 24-48 hour half-life (maintains natural pulsatility—ideal for cycling). Australian clinics exclusively use non-ACRP in 2026.

Will this show on a drug test?

Peptides are not detected on standard EPOA (anti-doping) panels used by Australian sports bodies, but WADA explicitly bans CJC-1295 and ipamorelin for competitive athletes in 2026. Telehealth clinics provide discreet packaging.

---

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. CJC-1295 and ipamorelin are prescription-only medicines (Schedule 4) in Australia as of 2026. Consult an Australian-registered telehealth physician before starting any peptide protocol. Varney Health provides clinical oversight for hormone optimisation but does not diagnose or treat without individual assessment.